IRLAB invites to a conference call in connection with the signed licensing deal with Ipsen for drug candidate mesdopetam

IRLAB (Nasdaq Stockholm: IRLAB A) announced late yesterday that a licensing agreement has been entered with the global biopharmaceutical company Ipsen for the drug candidate mesdopetam. In connection with this, IRLAB invites investors, analysts and media to a conference call on July 16, 2021, at 10:00 CET. IRLAB (Nasdaq Stockholm: IRLAB A) announced late yesterday that a licensing agreement has been entered with the global biopharmaceutical company Ipsen for the drug candidate mesdopetam. In connection with this, IRLAB invites investors, analysts and media to a conference call on July 16, 2021, at 10:00 CET. The presentation will be held by IRLAB’s CEO Nicholas Waters and CFO Viktor Siewertz in English and will conclude with a Q&A session. Questions can be asked live or in written form through the webcast. Date and time Friday July 16, 2021, at 10:00 CET. Webcast link https://bit.ly/IRLAB-License-Webinar Phone number +46 8 505 218 97 with code 545658623# The presentation will be recorded and may be published afterwards. For more information Nicholas Waters, CEO Phone: +46 730 75 77 01 E-mail: [email protected] Viktor Siewertz, CFO Phone: +46 727 10 70 70 E-mail: [email protected] About IRLAB IRLAB is a Swedish research and development company that focuses on developing novel treatments in Parkinson’s disease. The company's most advanced candidates, mesdopetam (IRL790) and pirepemat (IRL752), have completed Phase IIa studies and are designed to treat some of the most difficult symptoms related to Parkinson's disease: involuntary movements (PD-LIDs), psychosis (PDP) and symptoms linked to cognitive decline such as impaired balance and increased risk of falls (PD-Falls). Through the proprietary research platform, ISP (the Integrative Screening Process), IRLAB discovers and develops unique drug candidates for central nervous system (CNS)-related disorders where large and growing medical needs exist. In addition to the clinical candidates, the ISP platform has also generated several CNS programs that are now in preclinical phase. The project portfolio comprises a combination of the fully-funded mesdopetam program, run in collaboration with global partner Ipsen, as well as innovative in-house programs from preclinical to Phase IIb. IRLAB is listed on Nasdaq Stockholm Main Market. More information on www.irlab.se .

The release as fetched from its publisher. irlab.se ↗